Key Highlights
- Shares trading down 0.38% to $15.57 in today's session.
- Trading Volume reached 409.17 thousand shares.
- The company reported an EPS of negative $3.10.
- The trial targets relapsed or refractory acute myeloid leukemia, a disease with no approved immunotherapies.
First Patient Dosed in Potentially Registrational Study
Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a clinical-stage biopharmaceutical company developing T cell engager therapies, dosed its first patient in a potentially registrational Phase 2 study of CLN-049, an experimental treatment targeting FLT3-expressing cells in relapsed or refractory acute myeloid leukemia. The disease remains difficult to treat, with no currently approved immunotherapies and five-year survival rates of 10% or lower in the relapsed or refractory setting.
Study Design Follows Positive FDA Meeting
The study follows a successful end-of-Phase 1 meeting with the FDA and incorporates a brief dose-optimization phase before advancing to a single-arm expansion cohort. The company is also starting a separate Phase 1/2 combination study pairing CLN-049 with standard chemotherapy agents in newly diagnosed patients.
Shares Essentially Flat Despite Pipeline Milestone
Shares were little changed today, with an EPS of negative $3.10 reflecting the company's continued Investment across its broader immunology and oncology pipeline. The stock continues to trade well below its mid-September level, as the broader healthcare sector has faced pressure from elevated Treasury yields.
Outlook: Dose Escalation Update Expected in December
The company expects to provide an update from its earlier dose escalation study of CLN-049 in December, which may offer additional clarity on the drug's safety and early efficacy profile ahead of further Phase 2 enrollment.
FAQs
Q: What did Cullinan Therapeutics announce today?
A: The company announced that the first patient has been dosed in its potentially registrational Phase 2 study of CLN-049 in relapsed or refractory acute myeloid leukemia.
Q: Why did the stock stay relatively flat on this news?
A: Shares were little changed, suggesting the milestone was largely expected and the broader healthcare sector has faced separate pressure from rising Treasury yields.
Q: When is the next clinical update expected?
A: The company expects to provide an update from its earlier dose escalation study of CLN-049 in December.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.